Status
Conditions
Treatments
About
Oleactiv® have previously demonstrated beneficial effects in an animal model of diet-induced atherosclerosis. After a 12-week supplementation, a substantial reduction of aortic fatty streak area has been observed. Also, Oleactiv®-supplemented hamsters displayed significant decrease of both non-HDL-cholesterol and triglycerides levels. Also, phenolic compounds from Oleactiv® demonstrated that increase of cholesterol efflux capacity (CEC) is one of the mechanisms that may explain preventive effect on atheroma development.
These effects observed in animals will thus be investigated in human. The main hypothesis of the present study is that phenolic compounds from Oleactiv® may improve LDL oxidability in volunteers with moderate hypercholesterolemia after 3 weeks of consumption.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Dyslipidemia or hyperlipidemia:
Hypertensive-treated
Diabetes treated or not with medication
Taking drugs known to have an impact on lipid metabolism (statin, ezetimibe, colestyramine, fibrate, etc.) in the month preceding inclusion and / or likely to consume them during the test
Consuming food supplements or functional foods known to have an influence on cholesterolemia (phytosterol, phytostanol, red rice yeast, policosanols, beta-glucans at a dose greater than 3 g / d) in the month preceding the inclusion and / or likely to take during the test
Consuming probiotics in the form of a food supplement in the month preceding inclusion and / or likely to take them during the test
Following or having followed a hypocaloric diet (energy intake <1,500 kCal / day) in the month preceding inclusion and / or likely to undertake this diet during the test
Who donated blood in the 3 months preceding inclusion
Diagnosed eating disorders (bulimia, anorexia nervosa, vomiting)
High level athlete (physical activity for 1 hour per day)
Smoking more than 5 cigarettes per day
Bariatric surgery or who has a gastroplasty ring
Consuming more than 3 standard drinks of alcoholic beverage daily,
Consuming drugs,
Suffering from serious illnesses such as cancer, recent myocardial infarction, serious digestive pathologies or others diseases found to be inconsistent with the conduct of the study by the investigator,
Taking part in another clinical trial or being in the exclusion period of a previous clinical trial,
Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision,
Presenting a psychological or linguistic incapability to sign the informed consent,
Any other condition which in the investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject.
Known allergy to one of the component of the supplement (Grape, olive, artichoke, blackcurrant or pomegranate) or to corn.
Primary purpose
Allocation
Interventional model
Masking
26 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal